An ALPHA7 Nicotinic Acetylcholine Receptor Agonist (GTS-21) Promotes C2C12 Myonuclear Accretion in Association with Release of Interleukin-6 (IL-6) and Improves Survival in Burned Mice

ABSTRACT The role of interleukin-6 (IL-6) in physiological processes and disease is poorly understood. The hypothesis tested in this study was that selective alpha7 acetylcholine receptor (&agr;7AChR) agonist, GTS-21, releases IL-6 in association with myonuclear accretion and enhances insulin signaling in muscle cells, and improves survival of burn injured (BI) mice. The in vitro effects of GTS-21 were determined in C2C12 myoblasts and 7-day differentiated myotubes (myotubes). The in vivo effects of GTS-21 were tested in BI wild-type (WT) and IL-6 knockout (IL6KO) mice. GTS-21 dose-dependently (0 &mgr;M, 100 &mgr;M, and 200 &mgr;M) significantly increased IL-6 levels in myoblasts and myotubes at 6 and 9 h. GTS-21-induced IL-6 release in myotubes was attenuated by methyllycaconitine (&agr;7AChR antagonist), and by Stat-3 or Stat-5 inhibitors. GTS-21 increased MyoD and Pax7 protein expression, myonuclear accretion, and insulin-induced phosphorylation of Akt, GSK-3&bgr;, and Glut4 in myotubes. The glucose levels of burned IL6KO mice receiving GTS-21 decreased significantly compared with sham-burn IL6KO mice. Superimposition of BI on IL6KO mice caused 100% mortality; GTS-21 reduced mortality to 75% in the IL6KO mice. The 75% mortality in burned WT mice was reduced to 0% with GTS-21. The in vitro findings suggest that GTS-21-induced IL-6 release from muscle is mediated via &agr;7AChRs upstream of Stat-3 and -5 pathways and is associated with myonuclear accretion, possibly via MyoD and Pax7 expression. GTS-21 in vivo improves survival in burned WT mice and IL6KO mice, suggesting a potential therapeutic application of &agr;7AChR agonists in the treatment of BI.

[1]  L. V. van Loon,et al.  Satellite cells in human skeletal muscle plasticity , 2015, Front. Physiol..

[2]  J. Mauer,et al.  Versatile functions for IL-6 in metabolism and cancer. , 2015, Trends in immunology.

[3]  L. Partridge,et al.  Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin , 2014, Nature Immunology.

[4]  B. Pedersen.  Muscle as a secretory organ. , 2013, Comprehensive Physiology.

[5]  B. Pedersen,et al.  Interleukin‐6 myokine signaling in skeletal muscle: a double‐edged sword? , 2013, The FEBS journal.

[6]  E. Schleicher,et al.  Interleukin-6 promotes myogenic differentiation of mouse skeletal muscle cells: role of the STAT3 pathway. , 2013, American journal of physiology. Cell physiology.

[7]  A. Quintana,et al.  Interleukin-6, a Major Cytokine in the Central Nervous System , 2012, International journal of biological sciences.

[8]  M. Kaneki,et al.  Lipopolysaccharide Upregulates &agr;7 Acetylcholine Receptors: STIMULATION WITH GTS-21 MITIGATES GROWTH ARREST OF MACROPHAGES AND IMPROVES SURVIVAL IN BURNED MICE , 2012, Shock.

[9]  T. Zimmers,et al.  JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. , 2012, American journal of physiology. Endocrinology and metabolism.

[10]  R. Tompkins,et al.  Novel Mitochondria-Targeted Antioxidant Peptide Ameliorates Burn-Induced Apoptosis and Endoplasmic Reticulum Stress in the Skeletal Muscle of Mice , 2011, Shock.

[11]  M. Gassmann,et al.  Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells , 2011, Nature Medicine.

[12]  J. G. van der Hoeven,et al.  Effects of the &agr;7 Nicotinic Acetylcholine Receptor Agonist Gts-21 on the Innate Immune Response in Humans , 2011, Shock.

[13]  C. Libert,et al.  Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. , 2010, Cell metabolism.

[14]  P. Meikle,et al.  Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance , 2010, Diabetologia.

[15]  R. DeFronzo,et al.  Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes , 2009, Diabetes Care.

[16]  C. Metz,et al.  Cholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activation. , 2009, American journal of physiology. Cell physiology.

[17]  J. Gold,et al.  Initial phase 2 trial of a nicotinic agonist in schizophrenia. , 2008, The American journal of psychiatry.

[18]  A. Deshmukh,et al.  Interleukin-6 Directly Increases Glucose Metabolism in Resting Human Skeletal Muscle , 2007, Diabetes.

[19]  B. Pedersen,et al.  Beneficial health effects of exercise--the role of IL-6 as a myokine. , 2007, Trends in pharmacological sciences.

[20]  V. Pavlov,et al.  Selective &agr;7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis* , 2007, Critical care medicine.

[21]  M. Febbraio,et al.  Point: Interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. , 2007, Journal of applied physiology.

[22]  R. Mooney.  Counterpoint: Interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. , 2007, Journal of applied physiology.

[23]  V. Pavlov,et al.  Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis , 2006, The Journal of experimental medicine.

[24]  R. Papke,et al.  Multiple calcium channels and kinases mediate α7 nicotinic receptor neuroprotection in PC12 cells , 2005, Journal of neurochemistry.

[25]  M. Febbraio,et al.  Contraction-Induced Myokine Production and Release: Is Skeletal Muscle an Endocrine Organ? , 2005, Exercise and sport sciences reviews.

[26]  M. Schwaninger,et al.  Interleukin-6 (IL-6): A Possible Neuromodulator Induced by Neuronal Activity , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[27]  T. Luedde,et al.  Interleukin 6 and liver regeneration , 2000, Gut.

[28]  E. Benveniste,et al.  Oncostatin M Regulation of Interleukin‐6 Expression in Astrocytes , 2000, Journal of neurochemistry.

[29]  William R Kem,et al.  The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21) , 2000, Behavioural Brain Research.

[30]  W. L. Lin,et al.  Changes in circulating levels of interleukin 6 in burned patients. , 1999, Burns : journal of the International Society for Burn Injuries.

[31]  F. Trautinger,et al.  Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. , 1991, The Journal of investigative dermatology.

[32]  R. Tompkins,et al.  Prevention of Burn-Induced Inflammatory Responses and Muscle Wasting by GTS-21, a Specific Agonist for &agr;7 Nicotinic Acetylcholine Receptors , 2017, Shock.

[33]  P. Muñoz-Cánoves,et al.  Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. , 2008, Cell metabolism.

[34]  R. Papke,et al.  Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. , 2004, Molecular pharmacology.

[35]  C. Ohlsson,et al.  Interleukin-6-deficient mice develop mature-onset obesity , 2002, Nature Medicine.

[36]  P. Sehgal,et al.  Human Hepatoma Hep 3 B Cell Lines-Containing 135 STAT 5-Masking in p 53-Val Regulation of IL-6 Signaling by p 53 : STAT 3-and , 1998 .